Core Insights - Artificial intelligence, particularly generative AI, is significantly transforming the MedTech industry, with companies like Tempus AI, Inc. leading the way in AI-driven healthcare solutions [1] Product Developments - Tempus launched its HRD-RNA algorithm in February 2026, a next-generation AI model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors [2] - In January 2026, Tempus introduced Paige Predict, an AI-powered digital pathology application that analyzes whole slide images to assist in testing decisions [3] - Tempus received FDA clearance in July 2025 for its ECG-Low EF software, which uses AI to identify patients with low left ventricular ejection fraction [3] - The company also launched Notetaker in May 2025, an AI clinical assistant that records patient sessions to generate clinical notes for electronic health records [3] Industry Collaborations - GE HealthCare is collaborating with NVIDIA to utilize AI and high-performance computing to enhance patient comfort and reduce radiologist burnout [4] - Stryker's Mako SmartRobotics platform integrates AI to improve surgical accuracy in knee and hip procedures, with significant adoption and a recurring revenue model [5] Financial Performance - Tempus' stock has decreased by 21.9% over the past year, while the industry has seen a decline of 37.8%, contrasting with a 14.8% increase in the S&P 500 [6] - The company's current forward Price-to-Sales ratio is 6.63X, higher than the industry average of 5.66X, indicating an expensive valuation [9] Earnings Estimates - Tempus' loss per share estimates for 2025 have remained stable over the past 30 days, with projections of -0.59 for the current year and -0.21 for the next year [10][11]

本文转载自第一财经 值班编辑 | 江江 视觉 | 诺言 根据美股机构投资者13F持仓披露情况，截至2025年底，段永平管理的H&H International Investment持仓 总市值约174.89亿美元，折合人民币超1200亿元。 在大幅减持第一大重仓股苹果的同时，段永平在Q4将英伟达仓位狂拉逾11倍，并轻仓"试水"三家极具代 表性的AI垂直领域公司，CoreWeave、Credo Technology、Tempus Ai，持仓分别占比0.12%、0.12%、 0.04%。 此外，段永平还增持了谷歌、拼多多，并大幅减持了光刻机巨头阿斯麦（减持幅度87.63%）。 星标关注《盐财经》 洞察趋势，睿智人生 /// 大家都在看 /// 点 在看 把盐撒给更多的人 | Stock | History | Sector | Shares Held or | Market | % of | Previous | | Change in | 9/2 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | Principal | ...

Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week's Earnings - 24/7 Wall St.[S&P 5006,899.90 +0.70%][Dow Jones49,797.00 +0.47%][Nasdaq 10025,020.20 +1.21%][Russell 20002,674.93 +1.03%][FTSE 10010,681.60 +1.02%][Nikkei 22557,638.00 +1.03%][Stock Market Live February 19, 2026: S&P 500 (SPY) Up Ahead of Key Fed News][Investing]# Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week's Earnings### Quick ReadTempus AI (TEM) launched an AI algorithm identifying cancer patients res ...

Quick Read Tempus AI (TEM) launched an AI algorithm identifying cancer patients responsive to platinum-based chemotherapy using RNA analysis. Tempus reported preliminary Q4 revenue of $367M, up 83% year-over-year. Total contract value exceeded $1.1B. Analysts set a consensus target of $85.69 for Tempus with nearly 50% upside. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. Tempus AI, Inc. (NASDAQ:TE ...

Tempus AI (NASDAQ:TEM) rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors.The next-generation model analyzes gene expression to help identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, offering what the company says is a more dynamic assessment of tumor biology than traditional genomic methods. In a real-world validation study, HRD-RNA–positive metast ...

Core Insights - Tempus AI, Inc. (TEM) is set to report its fourth-quarter 2025 results on February 24, with expectations of an 82.8% year-over-year revenue increase to $366.8 million [2][7] - The company reported an adjusted loss of 11 cents per share in the last quarter, which was better than the Zacks Consensus Estimate of a loss of 16 cents [1] - Tempus has seen a share price decline of 32.9% in the fourth quarter due to macroeconomic challenges, despite strong momentum from strategic acquisitions and product launches [3][7] Financial Performance - The Zacks Consensus Estimate for loss per share has remained unchanged at 2 cents over the past 30 days [2] - The company's earnings estimate revision trend shows consistent expectations for the current quarter and the next, with losses projected at -0.02 for Q4 and -0.13 for Q1 2026 [3] - In the previous quarter, Tempus achieved a gross profit improvement of 98.4% year-over-year, and adjusted EBITDA turned positive, indicating progress towards profitability [14] Market Position and Competitive Landscape - Tempus trades at a forward price-to-sales (P/S) ratio of 5.82X, which is above the industry average of 5.66X and higher than competitors like 10x Genomics (3.83X) and SOPHiA GENETICS (3.69X) [16] - The Zacks Medical Info Systems industry experienced a loss of 21.6% during the same period, while the S&P 500 gained 3.3% [4] Strategic Developments - Recent collaborations include a multi-year partnership with Whitehawk Therapeutics for oncology treatments and a selection by the Advanced Research Projects Agency for Health to provide testing services [8] - The Genomics segment is expected to show improvement due to growth in oncology testing and hereditary sequencing, while the Data and Services business is likely to benefit from strong demand for proprietary data licensing and AI solutions [9][10] - Tempus has enhanced its capabilities through the acquisition of Paige, an AI leader in digital pathology, and expanded its collaboration with Northwestern Medicine to integrate AI into clinical workflows [12] Future Outlook - The AI market is anticipated to grow rapidly, positioning Tempus to capitalize on emerging opportunities in healthcare [17] - Despite recent upsides, the company's premium valuation and lack of near-term profitability may limit immediate gains [18]

英伟达(NVDA.US)位列第三，持仓约724万股，持仓市值约13亿美元，占投资组合比例为7.72%，持仓数量较上季度激增1110.62%%。 拼多多(PDD.US)位列第四，持仓约1156万股，持仓市值约13亿美元，占投资组合比例为7.48%，持仓数量较上季度增加34.55%。 谷歌-C(GOOG.US)位列第五，持仓约186万股，持仓市值约6亿美元，占投资组合比例为3.33%，持仓数量较上季度增加2.48%。 投资大佬段永平美股持仓主体H&H International Investment披露了截至2025年12月31日的第四季度持仓报告(13F)。据统计，H&H第四季度美股持仓总市值达 175亿美元，上一季度总市值为147亿美元。H&H的持仓组合中新增3只个股，增持了6只个股，减持了5只个股，清仓了0只个股。其中前十大持仓标的占总 市值的99.66%。 | 2025-12-31 | | | --- | --- | | 13F Activity | | | Market Value | $17.5b, Prior: $14.7b | | Inflows (Outflows) as % of | +13. ...

数据显示，段永平Q4共增持了六只股票，其中增持幅度最大的是英伟达，增持幅度第二大的股票是伯克希尔哈撒韦；同时，段永平也减持 了五只股票，减持幅度最大的是苹果。 | | | | % of | | Reported | % difference | | % (shares) | % change to | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | History | Ticker = Stock = | | Portfolio = | Shares* = | Price® @ | Current Price @ | Value @ | Activity = | Portfolio = | | P | BABA | ALIBABA GROUP HOLDING-SP ... | 2.15% | 2.560.500 | $146.58 | | $375,318,090 | -7.81% (-216.830) | -0.18% | | 1 | GOOG | ALPHABET INC-CL C | 3.33% | 1,855,400 | ...

The famous investor Cathie Wood is renowned for choosing companies focused on disruptive innovation, meaning companies that have the potential to change how industries work over the long term. So when her fund, ARK Invest (ARKK), adds or dumps shares, investors notice. Last week, ARK Invest added 210k shares of a healthcare tech company called Tempus AI (TEM). Wood has made repeated purchases of the stock, signaling her confidence in this rising AI bet. Tempus AI now holds 5.17% weightage in the ARK Innova ...

Key Takeaways Tempus AI integrates Median's FDA-cleared eyonis LCS into its Pixel imaging platform.TEM aims to enhance lung cancer detection, risk scoring and radiology workflow efficiency.Shares of TEM rose 2.3% post-announcement despite a 33.7% six-month decline.Tempus AI, Inc. (TEM) recently announced a collaboration with Median Technologies to integrate Median’s proprietary eyonis LCS solution into the Tempus Pixel platform. The integration is expected to expand Pixel’s AI capabilities in lung cancer sc ...